A
AVR
vs
S&P 500
S&P 500
Over the past 12 months, AVR has underperformed S&P 500, delivering a return of -21% compared to the S&P 500's +15% growth.
Stocks Performance
AVR vs S&P 500
Performance Gap
AVR vs S&P 500
Performance By Year
AVR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Anteris Technologies Global Corp
Glance View
Anteris Technologies Global Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Eagan, Minnesota and currently employs 138 full-time employees. The company went IPO on 2024-12-13. Anteris Technologies Global Corp. is a structural heart company engaged in discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. The company is engaged in the research and development of its biomimetic technology (ADAPT, DurAVR Transcatheter Heart Valve (THV), ComASUR Transfemoral Delivery System) to address unmet medical needs in the treatment of aortic stenosis. The DurAVR THV, with its single piece, native-shaped biomimetic design is built to mimic the performance of a healthy aortic valve and to restore normal laminar (smooth) blood flow. This class of technology can be used to treat new aortic stenosis patients and to treat aortic stenosis patients with failed valves (valve-in-valve). ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. ComASUR is its balloon-expandable delivery system.
